| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S12020-012-9696-X |
| P698 | PubMed publication ID | 22581255 |
| P50 | author | Lorenz C Hofbauer | Q56635718 |
| P2093 | author name string | Martina Rauner | |
| Tilman D Rachner | |||
| Christine Hamann | |||
| Elena Tsourdi | |||
| Kathrin Sinningen | |||
| P2860 | cites work | Human osteoclast-poor osteopetrosis with hypogammaglobulinemia due to TNFRSF11A (RANK) mutations | Q24310432 |
| Osteoprotegerin: a novel secreted protein involved in the regulation of bone density | Q24313918 | ||
| Central control of fever and female body temperature by RANKL/RANK | Q24321735 | ||
| A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function | Q24336057 | ||
| RANK is essential for osteoclast and lymph node development | Q24598872 | ||
| osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification | Q24603266 | ||
| Biomarkers of the osteoprotegerin pathway: clinical correlates, subclinical disease, incident cardiovascular disease, and mortality | Q24623768 | ||
| Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand | Q24653311 | ||
| Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL | Q24682139 | ||
| Postmenopausal osteoporosis treatment with antiresorptives: effects of discontinuation or long-term continuation on bone turnover and fracture risk--a perspective | Q26864207 | ||
| The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development | Q28142247 | ||
| Evidence for osteocyte regulation of bone homeostasis through RANKL expression | Q28247757 | ||
| Denosumab for prevention of fractures in postmenopausal women with osteoporosis | Q28254528 | ||
| RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis | Q28293009 | ||
| Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin | Q28295204 | ||
| Denosumab in postmenopausal women with low bone mineral density | Q28298728 | ||
| RANKL, RANK, osteoprotegerin: key partners of osteoimmunology and vascular diseases | Q28303938 | ||
| Orchiectomy upregulates free soluble RANKL in bone marrow of aged rats | Q28568938 | ||
| RANKL inhibition by osteoprotegerin prevents bone loss without affecting local or systemic inflammation parameters in two rat arthritis models: comparison with anti-TNFalpha or anti-IL-1 therapies | Q28570898 | ||
| OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis | Q28589430 | ||
| Receptor activator of NF-kB (RANK) expression in primary tumors associates with bone metastasis occurrence in breast cancer patients | Q28740575 | ||
| Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand | Q29619331 | ||
| The RANKL inhibitor OPG-Fc increases cortical and trabecular bone mass in young gonad-intact cynomolgus monkeys | Q33279942 | ||
| Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression | Q33944735 | ||
| Clinical review 114: hot topic. The role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in the pathogenesis and treatment of metabolic bone diseases. | Q33973495 | ||
| Bone changes in early rheumatoid arthritis | Q34254572 | ||
| Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology | Q34325803 | ||
| The skeletal metastatic complications of renal cell carcinoma. | Q34516181 | ||
| Duration of bone protection by a single osteoprotegerin injection in rats with adjuvant-induced arthritis | Q46425033 | ||
| Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial | Q46551911 | ||
| Sustained antiresorptive effects after a single treatment with human recombinant osteoprotegerin (OPG): a pharmacodynamic and pharmacokinetic analysis in rats. | Q46699294 | ||
| Osteoprotegerin protects against generalized bone loss in tumor necrosis factor-transgenic mice | Q47776871 | ||
| Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL. | Q50335960 | ||
| The effects of androgen deficiency on murine bone remodeling and bone mineral density are mediated via cells of the osteoblastic lineage. | Q50938354 | ||
| Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. | Q51054343 | ||
| Soluble RANKL induces high bone turnover and decreases bone volume, density, and strength in mice. | Q51703171 | ||
| Expression profiles of receptor activator of nuclear factor kappaB ligand, receptor activator of nuclear factor kappaB, and osteoprotegerin messenger RNA in aged and ovariectomized rat bones. | Q52131171 | ||
| Localization of RANKL (receptor activator of NF kappa B ligand) mRNA and protein in skeletal and extraskeletal tissues. | Q52172979 | ||
| Colonic dendritic cells, intestinal inflammation, and T cell-mediated bone destruction are modulated by recombinant osteoprotegerin. | Q52859590 | ||
| The cytokine RANKL produced by positively selected thymocytes fosters medullary thymic epithelial cells that express autoimmune regulator. | Q53453365 | ||
| Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells | Q56453539 | ||
| Epidermal RANKL controls regulatory T-cell numbers via activation of dendritic cells | Q57184743 | ||
| Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: A twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial | Q57752107 | ||
| Effect of Denosumab on Bone Mineral Density and Biochemical Markers of Bone Turnover: Six-Year Results of a Phase 2 Clinical Trial | Q58970719 | ||
| Two-Year Treatment With Denosumab (AMG 162) in a Randomized Phase 2 Study of Postmenopausal Women With Low BMD | Q58971166 | ||
| Osteoprotegerin mRNA is expressed in primary human osteoblast-like cells: down-regulation by glucocorticoids | Q61480394 | ||
| TNF-α antibodies and osteoprotegerin decrease systemic bone loss associated with inflammation through distinct mechanisms in collagen-induced arthritis | Q61833005 | ||
| Randomized Active-Controlled Phase II Study of Denosumab Efficacy and Safety in Patients With Breast Cancer-Related Bone Metastases | Q62392239 | ||
| IL-17 promotes bone erosion in murine collagen-induced arthritis through loss of the receptor activator of NF-kappa B ligand/osteoprotegerin balance | Q64378013 | ||
| Breast cancer cells interact with osteoblasts to support osteoclast formation | Q73025244 | ||
| Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells | Q73075587 | ||
| Osteoprotegerin/osteoclastogenesis inhibitory factor decreases human prostate cancer burden in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice | Q73344211 | ||
| Involvement of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis | Q73490940 | ||
| Expression of osteoclast differentiation factor at sites of bone erosion in collagen-induced arthritis | Q73678529 | ||
| Estrogen deficiency accelerates murine autoimmune arthritis associated with receptor activator of nuclear factor-kappa B ligand-mediated osteoclastogenesis | Q75273072 | ||
| Bone loss and the progression of abdominal aortic calcification over a 25 year period: the Framingham Heart Study | Q77084584 | ||
| Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment | Q77337113 | ||
| Bone marrow metastatic myeloma cells promote osteoclastogenesis through RANKL on endothelial cells | Q79361043 | ||
| Skeletal deterioration induced by RANKL infusion: a model for high-turnover bone disease | Q79984770 | ||
| Denosumab in postmenopausal women with low bone mineral density | Q80166076 | ||
| Changes in receptor activator of nuclear factor-kappaB, and its ligand, osteoprotegerin, bone-type alkaline phosphatase, and tartrate-resistant acid phosphatase in ovariectomized rats | Q80573911 | ||
| Detection of osteoprotegerin (OPG) and its ligand (RANKL) mRNA and protein in femur and tibia of the rat | Q81387247 | ||
| Comparison of the possible risk factors of bone mineral density in subjects with ulcerative colitis and healthy subjects | Q82180664 | ||
| Progression of osteoporosis in patients with COPD: a 3-year follow up study | Q83522812 | ||
| Denosumab-mediated increase in hand bone mineral density associated with decreased progression of bone erosion in rheumatoid arthritis patients | Q84062765 | ||
| Denosumab in men receiving androgen-deprivation therapy for prostate cancer | Q34570396 | ||
| Clinical features of metastatic bone disease and risk of skeletal morbidity | Q34576366 | ||
| Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer | Q34813227 | ||
| Androgens regulate bone resorption activity of isolated osteoclasts in vitro | Q34818200 | ||
| Role of RANK ligand in mediating increased bone resorption in early postmenopausal women | Q34912769 | ||
| RANK ligand and osteoprotegerin in myeloma bone disease. | Q34992857 | ||
| Repair of local bone erosions and reversal of systemic bone loss upon therapy with anti-tumor necrosis factor in combination with osteoprotegerin or parathyroid hormone in tumor necrosis factor-mediated arthritis | Q35083436 | ||
| Breast cancer metastasis to bone: it is not all about PTHrP. | Q35576773 | ||
| IL-6, RANKL, TNF-alpha/IL-1: interrelations in bone resorption pathophysiology | Q35640443 | ||
| Infections in postmenopausal women with osteoporosis treated with denosumab or placebo: coincidence or causal association? | Q35643989 | ||
| Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women | Q35644204 | ||
| Disturbance of the OPG/RANK/RANKL pathway and systemic inflammation in COPD patients with emphysema and osteoporosis | Q35677638 | ||
| TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis | Q35788463 | ||
| Osteoprotegerin reduces osteoclast numbers and prevents bone erosion in collagen-induced arthritis | Q35789185 | ||
| B cells and T cells are critical for the preservation of bone homeostasis and attainment of peak bone mass in vivo | Q35804512 | ||
| Soluble receptor activator of nuclear factor κB ligand/osteoprotegerin ratio is increased in systemic lupus erythematosus patients | Q35840828 | ||
| RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis | Q35885679 | ||
| Estrogen deficiency induces bone loss by increasing T cell proliferation and lifespan through IFN-gamma-induced class II transactivator. | Q35918333 | ||
| Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension | Q36153179 | ||
| Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength | Q36269835 | ||
| Fully human therapeutic monoclonal antibodies | Q36347397 | ||
| Regulation of peripheral lymph node genesis by the tumor necrosis factor family member TRANCE | Q36368551 | ||
| Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis | Q36368706 | ||
| Osteoporosis: now and the future | Q36564425 | ||
| Early induction of alterations in cancellous and cortical bone histology after orchiectomy in mature rats | Q36794733 | ||
| Osteoprotegerin inhibits vascular calcification without affecting atherosclerosis in ldlr(-/-) mice. | Q37188485 | ||
| Inhibition of receptor activator of NF-kappaB ligand by denosumab attenuates vascular calcium deposition in mice | Q37278407 | ||
| Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone | Q37383855 | ||
| New knowledge on critical osteoclast formation and activation pathways from study of rare genetic diseases of osteoclasts: focus on the RANK/RANKL axis. | Q37748586 | ||
| Clinical practice. Glucocorticoid-induced bone disease | Q37898140 | ||
| The use of combination therapy in the treatment of postmenopausal osteoporosis | Q37950921 | ||
| New understanding and treatments for osteoporosis | Q37969683 | ||
| Increased RANKL expression is related to tumour migration and metastasis of renal cell carcinomas | Q39849289 | ||
| Denosumab prevents metacarpal shaft cortical bone loss in patients with erosive rheumatoid arthritis | Q39882954 | ||
| Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone | Q39946634 | ||
| RANK ligand inhibition plus docetaxel improves survival and reduces tumor burden in a murine model of prostate cancer bone metastasis | Q39964150 | ||
| Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis | Q40038407 | ||
| Knocking down dickkopf-1 alleviates estrogen deficiency induction of bone loss. A histomorphological study in ovariectomized rats | Q40277043 | ||
| Regulation of cancer cell migration and bone metastasis by RANKL. | Q40298349 | ||
| The inhibition of RANKL causes greater suppression of bone resorption and hypercalcemia compared with bisphosphonates in two models of humoral hypercalcemia of malignancy. | Q40432075 | ||
| Testosterone increases osteoprotegerin mRNA expression in mouse osteoblast cells | Q40496407 | ||
| Regulation of osteoprotegerin production by androgens and anti-androgens in human osteoblastic lineage cells. | Q40713758 | ||
| RANK ligand, RANK, and OPG expression in type II collagen-induced arthritis mouse | Q40742292 | ||
| Androgens suppress osteoclast formation induced by RANKL and macrophage-colony stimulating factor | Q40784699 | ||
| Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis | Q40926683 | ||
| Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial | Q41489196 | ||
| The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. | Q41649459 | ||
| Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo | Q41753607 | ||
| Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study | Q41904942 | ||
| Interleukin-17: A new bone acting cytokine in vitro | Q42476956 | ||
| Osteoprotegerin and rank ligand expression in prostate cancer | Q42502915 | ||
| Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study | Q42829926 | ||
| Estrogen inhibits vascular calcification via vascular RANKL system: common mechanism of osteoporosis and vascular calcification | Q42994159 | ||
| Combination therapy with dexamethasone and osteoprotegerin protects against arthritis-induced bone alterations in antigen-induced arthritis of the rat. | Q43122456 | ||
| The evolving systemic and local biomarker milieu at different stages of disease progression in rat adjuvant-induced arthritis | Q43494262 | ||
| Receptor activator of nuclear factor kappaB ligand (RANKL) is a key molecule of osteoclast formation for bone metastasis in a newly developed model of human neuroblastoma. | Q43540277 | ||
| A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases | Q44291815 | ||
| Differential effects of androgens on cortical bone histomorphometry in gonadectomized male and female rats | Q44527170 | ||
| Vascular endothelial growth factor up-regulates expression of receptor activator of NF-kappa B (RANK) in endothelial cells. Concomitant increase of angiogenic responses to RANK ligand | Q44534331 | ||
| Effect of systemic glucocorticoid therapy on bone metabolism and the osteoprotegerin system in patients with active Crohn's disease | Q44618423 | ||
| Reductions in bone turnover, mineral, and structure associated with mechanical properties of lumbar vertebra and femur in glucocorticoid-treated growing minipigs | Q44658947 | ||
| Cancer and the microenvironment: myeloma-osteoclast interactions as a model | Q44802876 | ||
| Denosumab reduces the risk of osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX. | Q44907080 | ||
| RANKL is a marker and mediator of local and systemic bone loss in two rat models of inflammatory arthritis | Q44936799 | ||
| Increased RANK ligand in bone marrow of orchiectomized rats and prevention of their bone loss by the RANK ligand inhibitor osteoprotegerin. | Q45962202 | ||
| RANKL increases vascular smooth muscle cell calcification through a RANK-BMP4-dependent pathway | Q46072800 | ||
| A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women | Q46133598 | ||
| Additive bone-protective effects of anabolic treatment when used in conjunction with RANKL and tumor necrosis factor inhibition in two rat arthritis models | Q46159767 | ||
| RANKL inhibition with osteoprotegerin increases bone strength by improving cortical and trabecular bone architecture in ovariectomized rats | Q46212098 | ||
| Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial | Q46393065 | ||
| P433 | issue | 1 | |
| P304 | page(s) | 52-62 | |
| P577 | publication date | 2012-05-13 | |
| P1433 | published in | Endocrine | Q15757048 |
| P1476 | title | Skeletal and extraskeletal actions of denosumab | |
| P478 | volume | 42 |
| Q27000565 | A High-grade Sarcoma Arising in a Patient With Recurrent Benign Giant Cell Tumor of the Proximal Tibia While Receiving Treatment With Denosumab |
| Q38271156 | Alternative pathways of osteoclastogenesis in inflammatory arthritis |
| Q36065421 | Assessment of the Effect of Methotrexate Therapy on Bone Metabolism in Patients with Rheumatoid Arthritis. |
| Q36753894 | Associations between Systemic Markers of Bone Turnover or Bone Mineral Density and Anti-Resorptive Agent-Related Osteonecrosis of the Jaw in Patients Treated with Anti-Resorptive Agents |
| Q99240502 | Bone Metabolism in SARS-CoV-2 Disease: Possible Osteoimmunology and Gender Implications |
| Q34746798 | Effects of antibody to receptor activator of nuclear factor κ-B ligand on inflammation and cartilage degradation in collagen antibody-induced arthritis in mice. |
| Q59419714 | Effects of denosumab on peripheral lymphocyte subpopulations |
| Q38051265 | Osteoporosis in chronic inflammatory disease: the role of malnutrition. |
| Q38077109 | Osteoporosis in men: recent progress |
| Q37006852 | Pathophysiology of Osteonecrosis of the Jaws |
| Q36945036 | Periapical disease and bisphosphonates induce osteonecrosis of the jaws in mice |
| Q38156703 | Prevalence of osteoporosis in prostate cancer survivors: a meta-analysis. |
| Q51345508 | Serum extracellular secreted antagonists of the canonical Wnt/β-catenin signaling pathway in patients with Cushing's syndrome. |
| Q28533497 | Sinomenine suppresses osteoclast formation and Mycobacterium tuberculosis H37Ra-induced bone loss by modulating RANKL signaling pathways |
| Q38193181 | The inhibition of RANK-ligand in the management of postmenopausal osteoporosis and related fractures: the role of denosumab |
| Q38056541 | The role of osteoprotegerin in cardiovascular disease |
| Q47225671 | Transcriptional network systems in cartilage development and disease |
Search more.